Selenium and anticarcinogenesis: Underlying mechanisms

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 6, 2008, Pages 718-726

  Jackson, Matthew I ^a   Combs Jr , Gerald F ^a  

^a GRAND FORKS HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

Anticarcinogenesis; Cancer prevention; Carcinogenesis; Protein thiol; Redox cycling; Selenium

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; HYDROGEN SELENIDE; METHIONINE; METHYLSELENOCYSTEINE; METHYLSELENOL; PROTEIN KINASE (CALCIUM,CALMODULIN) II; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SELENIDE; SELENIUM; SELENIUM DERIVATIVE; SELENOCYSTEINE; SELENOMETHIONINE; SELENOPROTEIN; SODIUM SELENITE; THIOL; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL NEOPLASM; GENE CONTROL; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; LONG TERM CARE; METABOLISM; METASTASIS; METASTASIS INHIBITION; MOLECULAR MIMICRY; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; TESTIS CANCER; TUMOR CELL; UTERINE CERVIX CANCER;

ANTICARCINOGENIC AGENTS; APOPTOSIS; DNA DAMAGE; HUMANS; NEOPLASMS; ORGANOSELENIUM COMPOUNDS; SELENIUM; SELENIUM COMPOUNDS; SELENOMETHIONINE; SELENOPROTEINS; SIGNAL TRANSDUCTION;

EID: 55149090265     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3283139674     Document Type: Review

References (67)

1. Gramer S, Eubel J, Lee B, et al. Human selenoproteins at a glance. Cell Mol Life Sci 2005; 62:2414-2437.
2. Food and Nutrition Board. Dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids. Washington, District of Columbia: National Academy Press; 2000. pp. 285-324.
3. Shamberger R, Frost D. Possible protective effect of selenium against human cancer. Can Med Assoc J 1969; 104:82-88.
4. Combs G, Gray W. Chemopreventive agents: selenium. Pharmacol Ther 1998; 3:179-198.
5. Rayman M. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 2005; 64:527-542.
6. Combs G, Lü J. Selenium as a cancer preventive agent. In: Hatfield D, editor. Selenium: molecular biology and role in health, 2nd ed. New York: Kluwer Academic; 2006. pp. 205-218.
7. Gromadzińsk J, Reszka E, Bruzelius K, et al. Selenium and cancer: biomarkers of selenium status and molecular action of supplements. Eur J Nutr 2008; 47:29-50.
8. Clark L, Combs G, Turnbull B, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996; 276:1957-1963.
9. Peters U, Littman A, Kristal A, et al. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and Lifestyle (VITAL) study cohort. Cancer Causes Control 2008; 19:75-87.
10. Jiang C, Wang Z, Ganther H, et al. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002; 1:1059-1067.
11. Ip C. Lessons learned from basic research in selenium and cancer prevention. J Nutr 1998; 128:1845-1854.
12. Hesketh J. Nutrigenomics and selenium: gene expression patterns, physiological targets and genetics. Ann Rev Nutr 2008; 28:11.1-11.21.
13. Pagmantidis V, Méplan C, van Schothorst E, et al. Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases expression of lymphocyte protein biosynthesis genes. Am J Clin Nutr 2008; 87:181-189. This is the first study to assess the effects of modest Se supplementation (100 μ,g/ day for 6 weeks) on global gene expression in peripheral lymphocytes. Conducted with a cohort of Europeans, the supplementation increased plasma total Se and SepP levels. Consistent changes were found in the expression of 250 genes assessed in lymphocytes; these included upregulation of genes associated with protein synthesis, and may supply novel biomarkers for Se status from a readily accessible tissue pool.
14. Ravn-Haren G, Krath B, Overad K, et al. Effect of long-term selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic metabolizing enzymes in healthy volunteers from the Danish Prevention of Cancer by Intervention by Selenium (PRECISE) pilot study. Br J Nutr 2008; 99:1190-1198. This study was among the first to determine the effect of long-term Se supplementation on gene expression in healthy humans. Participants (105) were randomized to 0, 100, 200 or 300 μg Se (as Se yeast) per day for 5 years. Sesupplemented individuals showed downregulation of genes for some phase 2 enzymes and upregulation of aryl hydrocarbon receptor repressor (AhRR) gene expression.
15. Selenius M, Fernandes A, Brodin O, et al. Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system. Biochem Pharmacol 2008; 75:2092-2099.
16. Golombieski R, Graichen D, da Roch J, et al. Over-activation of the Drosophila melanogaster hsp83 gene by selenium intoxication. Gen Mol Biol 2008; 31:128-135.
17. Thirunavukkarasu C, Prfemkumar K, Sheriff A, et al. Sodium selenite enhances glutathione peroxidase activity and DNA single strand breaks in hepatoma induced by N-nitrosodiethylamine and promoted by Phenobarbital. Mol Cell Biochem 2008; 310:129-139.
18. Letavayová L, Vlasáková D, Spallholz J. Toxicity and mutagenicity of selenium compounds in Saccharomyces cerevisiae. Mutat Res 2008; 638:1-10.
19. Rudolf E, Rudolf K, Červinka M. Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol 2008; 24:123-141.
20. Seitomer E, Balar B, He D, et al. Analysis of Saccharomyces cerevisiae null allele strains identified a larger role for DNA damage versus oxidative stress pathways in growth inhibition by selenium. Mol Nutr Food Res 2008 [Epub ahead of print].
21. Letavayová L, Vlasáková D, Vlčková V, et al. Rad52 has a role in the repair of sodium selenite-induced DNA damage in Saccharomyces cerevisiae. Mutat Res 2008; 652:198-203. This study provides the first evidence that homologous recombination is involved in the process of DNA damage from exposure to high levels of selenite.
22. Hu Y, McIntosh G, Leu R, et al. Suppression of colorectal oncogenesis by selenium-enriched milk proteins: apoptosis and K-ras mutations. Cancer Res 2008; 68:4936-4944.
23. Lee J, Shin S, Kang S, et al. A novel activation-induced suicidal degradation mechanism for Akt by selenium, Int J Mol Med 2008; 21:91-97. This study showed that SeMet transiently activates Akt by kinase-mediated phosphorylation and subsequently inactivates it in a PTEN-tumor suppressor-dependent fashion resulting in degradation through both caspase and proteosome pathways.
24. Wang Z, Hu H, Li G, et al. Methylseleninic acid inhibits microvascular endothelial G,cell cycle progression and decreases tumor microvessel density, Int J Cancer 2008; 122:15-24. The report extends previous work by the same group that has indicated a role of Se in impairing tumorigenesis by inhibition of neoangiogenesis. This study demonstrates that effect for a proximal metabolic precursor of the putative anticarcinogenic Se metabolite, methylselenol, showing its efficacy in promoting cell cycle arrest in telemorase-immotalized microvascular endothelial cells, and reducing microvessel density in tumors developing from prostate cancer cell xenografts.
25. Jariwalla R, Gangapurkar B, Nakamura D. Differential sensitivity of various human tumor-derived cell types to apoptosis by organic derivatives of selenium. Br J Nutr 2008 [Epub ahead of print]. This study shows that cell types differ in sensitivity to Se-induced apoptosis. They show that breast carcinoma cells to be very sensitive, showing apoptotic responses to 0.113 μmol Se. Higher levels of Se-MeSeCys and SeMet were required to produce comparable apoptotic effects in hepatoma and neuroblastoma cells, and higher levels were required for colon cancer cells and nonmalignant mammary epithelial cells.
26. Hu H, Li G, Wang L, et al. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and Survivin. Clin Cancer Res 2008; 14:1150-1158.
27. Van L, Yee J, McGuire M, et al. Effect of dietary supplementation of selenite on pulmonary metastasis of melanoma cells in mice. Nutr Cancer 1997; 28: 165-169.
28. Yan L, Yee J, Li D, McGuire M, et al. Dietary supplementation of selenomethionine reduces metastasis of melanoma cells in mice. Anticancer Res 1999; 19:1337-1342.
29. Hurst R, Elliot RM, Goldson AJ, Fairweather-Tait SJ. Se- methylselenocysteine alters collagen gene and protein expression in human prostate cells. Cancer Lett 2008; 269:117-126.
30. Kim Y, Lee Y, Choe J, et al. CD44-EGFR interaction mediates hyaluronic acid-promoted cell motility by activating PKC signaling involving Akt, Rac1, Phox, ROS, FAK and MMP-2. J Biol Chem 2008; 283:22513-22528.
31. Li G, Lee H, Wang Z, et al. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008; 29:1005-1012. This study shows that tumor accumulation of total Se is not correlated with anticarcinogenesis; SeMet supplementation caused up to eight-fold higher Se accumulation than other supplements with no appreciable effect on tumor burden.
32. Bhattacharya A, Seshadri M, Oven S, et al. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 2008; 14:3926-3932. The study extends the group's previous demonstration of therapeutic synergy of MeSeCys and anticancer drugs by showing that MeSeCys treatment of mice given FaDu human head and neck squamous cell carcinoma xenografts showed significant increases in tumor microvascular maturation and tumor uptake of doxorubicin.
33. Murawaki Y, Tsuchiya H, Kanbe T, et al. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett 2008; 259:218-230. This is the first study to compare the expression of multiple selenoproteins in tumor and nontumorous tissues from human cancer patients. They found that the oxidative modifications of proteins were more in tumor tissues, but that the expression of two glutathione peroxidase isoforms (GPX1, GPX3) and SepP were decreased and GPX2 was increased.
34. Baliga M, Wang H, Zhuo P, et al. Selenium and Gpx-1 overexpression protect mammalian cells against UV-induced DNA damage. Biol Trace Element Res 2007; 115:227-241.
35. Peters U, Chatterjee N, Hayes R, et al. Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2008; 17:1144-1154. This study found positive associations between genetic variants at or near the SEPP1 and TXNRD1 loci and risk of advanced colorectal adenoma.
36. Arsova-Sarafinovska Z, Matevska N, Eken A, et al. Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk, Int Ural Nephrol 2008 [Epub ahead of print]. This study showed that carriers of the variant Leu allele of the Pro198Leu polymorphism of cytosolic GPX1 were at decreased risk to prostate cancer in a cohort of Macedonian men.
37. Jablonska E, Gromadzinska J, Sobala W, et al. Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur J Nutr 2008; 47:47-54. This study showed different risks to lung cancer for individuals of different genotype with respect to a polymorphism of the 15kDa selenoprotein (Sep15). Although plasma Se was inversely related to lung cancer risk in both genotype groups, at plasma Se levels above 80 ng/ml risk increased for individuals of the 1125 GG or GA genotypes. Individuals with the 1125 AA genotype appeared to benefit most from higher Se status.
38. Anestal K, Prast-Nielsen S, Cenas N, et al. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS ONE 2008; 3:e1846.
39. Méplan C, Crosley L, Nicol F, et al. Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study). FASEB J 2007; 21:3063-3074. This study demonstrated relationships of two SNPs of SepP with plasma Se level and its response to supplementation. The SNP 24731 genotype was a determinant of presupplementation plasma Se level, whereas the SNP 25191 genotype was a determinant of the change in plasma Se level in response to supplementation.
40. Tarze A, Dauplais M, Grigoras I, et al. Extracellular production of hydrogen selenide accounts for thiol-assisted toxicity of selenite against Saccharomyces cerevisiae. J Biol Chem 2007; 282:8759-8767.
41. Shalini S, Bansal M. Co-operative effect of glutathione depletion and selenium induced oxidative stress on API and NFkB expression in testicular cells in vitro: insights to regulation of spermatogenesis. Biol Res 2007; 40: 307-317.
42. Zhang J, Wang H, Peng D, et al. Further insight into the impact of sodium selenite on selenoenzymes: high-dose selenite enhances hepatic thioredoxine reductase 1 activity as a consequence of liver injury. Toxicol Lett 2008; 176:223-229.
43. Assmann A, Briviba K, Sies H. Reduction of selenomethionine selenoxide to selenomethionine by glutathione. Arch Biochem Biophys 1998; 340:201-203.
44. Le D, Liang X, Fomenko D, et al. Analysis of methionine/ selenomethionine oxidation and methionine sulfoxide reductase function using methionine-rich proteins and antibodies against their oxidized forms. Biochemistry 2008; 47:6685-6694. This study demonstrates that peptidyl Se(O)Met can be reduced readily to SeMet, providing a mechanism for alteration of methionine sulfoxide signaling.
45. Carruthers N, Stemmer P. Methionine oxidation in the calmodulin-binding domain of calcineurin disrupts calmodulin binding and calcineurin activation. Biochemistry 2008; 47:3085-3095.
46. Erickson JR, Joiner ML, Guan X, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008; 133: 462-474.
47. Park H, Park E, Kim M, et al. Selenite inhibits the c-Jun N-terminal kinase/ stress-activated protein kinase (JNK/SAPK) through a thiol redox mechanism. J Biol Chem 2000; 275:2527-2531.
48. Gupta N, Porter T. Inhibition of human squalene monooxygenase by selenium compounds. J Biochem Mol Toxicol 2002; 16:18-23.
49. Beld J, Woycechowsky K, Hilvert D. Catalysis of oxidative protein folding by small-molecule diselenides. Biochemistry 2008; 47:6985-6987.
50. Bachrach M, Demoin D, Luk M, et al. Nucleophilic attack at selenium in diselenides and selenosulf ides. A computational study. J Phys Chem A 2004; 108:4040-4046.
51. Sherry P, Huang F, Huang K. Ischemia-elicited oxidative modulation of Ca2+/ calmodulin-dependent protein kinase II. J Biol Chem 2008; 283:5389-5401.
52. Sinha R, Pinto J, Facompre N, et al. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells. Nutr Cancer 2008; 60:267-275.
53. 34S]-labeled methionine, selenomethionine, and telluromethionine. Anal Bioanal Chem 2008; 390:45-51.
54. Butler J, Beilstein M, Whanger PD. Influence of dietary methionine on the metabolism of selenomethionine in rats. J Nutr 1989; 119:1001-1009.
55. Durando X, Thivat E, Farges MC, et al. Optimal methionine-free diet duration for nitrourea treatment: a Phase I clinical trial. Nutr Cancer 2008; 60:23-30.
56. Huber R, Criddle R. The isolation and properties of beta-galactosidase from Escherichia coli grown on sodium selenate. Biochim Biophys Acta 1967; 141:587-599.
57. Boles J, Cisneros R, Weir M, et al. Purification and characterization of selenomethionyl thymidylate synthase from Escherichia coli: comparison with the wild-type enzyme. Biochemistry 1991; 30:11073-11080.
58. Gassner N, Baase W, Hausrath A, et al. Substitution with selenomethionine can enhance the stability of methionine-rich proteins. J Mol Biol 1999; 294: 17-20.
59. Boles J, Tolleson W, Schmidt J, et al. Selenomethionyl dihydrofolte reductase from Escherichia coli. J Biol Chem 1992; 267:22217-22223.
60. De Bree F, Brzozowski A, Gellerfors P, et al. Preparation and characterization of the selenomethionine analogue of insulin-like growth factor-l. Protein Expr Purif 1998; 3:319-325.
61. Kajander E, Harvima R, Eloranta T, et al. Metabolism, cellular actions, and cytotoxicity of selenomethionine in cultured cells. Biol Trace Elem Res 1991; 28:57-68.
62. Mudd S, Cantoni G. Selenomethionine in enzymatic transmethylations. Nature 1957; 180:1052.
63. Wrobel K, Wrobel K, Caruso J. Selenium speciation in low molecular weight fraction of Se-enriched yeasts by HPLC-ICP-MS: detection of selenoadeno-sylmethionine. J Anal At Spectrom 2002; 9:1048-1054.
64. Kajander E, Harvima R, Kauppinen L, et al. Effects of selenomethionine on cell growth and on S-adenosylmethionine metabolism in cultured malignant cells. Biochem J 1990; 267:767-774.
65. Malkowski M, Quartley E, Fnedman A, et al. Blocking S-adenosylmethionine synthesis in yeast allows selenomethionine incorporation and multiwave-length anomalous dispersion phasing. Proc Natl Acad Sci USA 2007; 104:6678-6683.
66. Redman C, Xu M, Peng Y, et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 1997; 18:1195-1202.
67. Bjelakovic G, Beninati S, Pavlovic D, et al. Selenomethionine induces polyamine biosynthesis in regenerating rat liver tissue. Amino acids 2007; 33:525-529. Together with previous findings in tumor tissues, this study indicates that there might be disparate effects of SeMet supplementation on polyamine levels between proliferating normal and cancer tissues.